Triptorelin

Triptorelin
Systematic (IUPAC) name
?
Identifiers
CAS number	57773-63-4
ATC code	L02AE04
PubChem	?
Chemical data
Formula	C64H82N18O13
Mol. mass	1311.5 g/mol
Pharmacokinetic data
Bioavailability	?
Metabolism	?
Half life	?
Excretion	Renal
Therapeutic considerations
Pregnancy cat.	D
Legal status	℞-only
Routes	Implant

WikiDoc Resources for Triptorelin
Articles
Most recent articles on Triptorelin Most cited articles on Triptorelin Review articles on Triptorelin Articles on Triptorelin in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Triptorelin Images of Triptorelin Photos of Triptorelin Podcasts & MP3s on Triptorelin Videos on Triptorelin
Evidence Based Medicine
Cochrane Collaboration on Triptorelin Bandolier on Triptorelin TRIP on Triptorelin
Clinical Trials
Ongoing Trials on Triptorelin at Clinical Trials.gov Trial results on Triptorelin Clinical Trials on Triptorelin at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Triptorelin NICE Guidance on Triptorelin NHS PRODIGY Guidance FDA on Triptorelin CDC on Triptorelin
Books
Books on Triptorelin
News
Triptorelin in the news Be alerted to news on Triptorelin News trends on Triptorelin
Commentary
Blogs on Triptorelin
Definitions
Definitions of Triptorelin
Patient Resources / Community
Patient resources on Triptorelin Discussion groups on Triptorelin Patient Handouts on Triptorelin Directions to Hospitals Treating Triptorelin Risk calculators and risk factors for Triptorelin
Healthcare Provider Resources
Symptoms of Triptorelin Causes & Risk Factors for Triptorelin Diagnostic studies for Triptorelin Treatment of Triptorelin
Continuing Medical Education (CME)
CME Programs on Triptorelin
International
Triptorelin en Espanol Triptorelin en Francais
Business
Triptorelin in the Marketplace Patents on Triptorelin
Experimental / Informatics
List of terms related to Triptorelin

Triptorelin (acetate or palmoate) is a gonadotropin releasing hormone agonist (GnRH agonist). By causing constant stimulation of the pituitary, it decreases pituitary secretion of gonadotropins luteinizing hormone (LH) and follicle stimulating hormone (FSH). Like other GnRH agonists, triptorelin may be used in the treatment of hormone-responsive cancers such as prostate cancer or breast cancer, precocious puberty, estrogen-dependent conditions (such as endometriosis or uterine fibroids), and in assisted reproduction. Triptorelin is marketed under the brand names Decapeptyl^® (Ferring Pharmaceuticals) and Diphereline^® and Gonapeptyl^®.
Triptorelin is sold by Pfizer in the United States as Trelstar^®. During the treatment of prostate cancer it does cause a surge of testosterone (an initial uplevel of testosterone levels). In men a reduction of serum testosterone levels into the range normally seen after surgical castration occurs appr. 2 to 4 weeks after initiation of therapy. In contrast gonadotropin releasing hormone Receptor antagonists does not cause a surge, but a sudden shut-down of testosterone level.
Systematic IUPAC Name: [d-Trp6]GnRH

References

• Pharmacokinetics and pharmacodynamics of GnRH agonists: clinical implications in pediatrics. J Pediatr Endocrinol Metab. 2000 Jul;13 Suppl 1:723-37. Review. PMID 10969915

• GnRH analogues—agonists and antagonists A.M. Padula,

University of Melbourne [1]